Most functions are unavailable without JavaScript. Please activate JavaScript and reload this page.
Please stand by while page is loading...
Cookies seem to be disabled in your browser, please check and activate them.
Cover 2010
Financial Key Figures/Pipeline
Share Trading Information
Our Mission
Contents Profile
2 Letter to the Shareholders
3 Letter to Shareholders
4 Our Products
5 Catena®
6 Catena®
7 Catena®
8 Fipamezole / Omigapil
9 Highlights 2010
10 2010 Revenue of CHF 20.6 Million and Preparing MAA Filing in LHON
11 2010 Revenue of CHF 20.6 Million and Preparing MAA Filing in LHON
12 Corporate Management
13 Our Inspiration
Contents Corporate Governance
CG-1
CG-2
CG-3
CG-4
CG-5
CG-6
CG-7
CG-8
CG-9
CG-10
CG-11
CG-12
CG-13
CG-14
CG-15
CG-16
CG-17
Contents Financial Report
F-1
F-2
F-3
F-4
F-5
F-6
F-7
F-8
F-9
F-10
F-11
F-12
F-13
F-14
F-15
F-16
F-17
F-18
F-19
F-20
F-21
F-22
F-23
F-24
F-25
F-26
F-27
F-28
F-29
F-30
F-31
F-32
F-33
F-34
F-35
F-36
F-37
F-38
F-39
F-40
F-41 Report of the Group Auditor
F-42 Report of the Group Auditor
F-43
Contents Statutory Financial Statements
F-45
F-46
F-47
F-48
F-49
F-50
F-51
F-52
F-53
F-54
F-55 Report of the Statutory Auditor
F-56 Report of the Statutory Auditor
Forward-looking Statement
Blank Page
Imprint
Back
Profile
Our Mission
Letter to the Shareholders
Our Products
Hightlights 2010
Corporate Management
Our Inspiration
Financial Report
Corporate Governance
General Information
Group Structure and Shareholders (DCG 1)
Capital Structure (DCG 2)
Board of Directors (DCG 3)
Executive Management (DCG and 3.5
Compensation, Shareholdings and Loans (DCG 5)
Shareholder's Participation (DCG 6)
Changes of Control and Defense Measures (DCG 7)
Auditors (DCG 8)
Information Policy (DCG 9)
Consolidated Balance Sheet
Consolidated Income Statement
Consolidated Statement of Cash Flows
Consolidated Statement of Changes in Equity
Notes to the Consolidated Financial Statements
Notes 1 to 10
1 General Information
2 Summary of Significant Accounting Policies
3 Critical Accounting Estimates, Assumptions and Judgments
4 Exchange Rates of Principal Currencies
5 Tangible Assets
6 Intangible Assets
7 Impairment Testing of Intangible Assets
8 Inventories
9 Trade and Other Receivables
10 Financial Assets and Liabilities – Short- and Long-term
Notes 11 to 20
11 Cash and Cash Equivalents
12 Share Capital
13 Deferred Taxes
14 Trade and Other Payables
15 Accrued Expenses
16 Short- and Long-term Provisions
17 Contingent Assets
18 Commitments and Contingent Liabilities
19 Stock Option Plans
20 Segment and Geographic Information
Notes 21 to 30
21 Gross Profit Breakdown
22 Other Operating Income
23 Operating Expenses by Function
24 Operating Expenses by Nature
25 Employee Expenses and Benefits
26 Financial Income/Expenses
27 Currency Translation Differences
28 Income Taxes
29 Earnings per Share
30 Related Party Transactions
Notes 31 to 32
31 Risk Management Objectives and Policies
32 Events after the Balance-Sheet Date
Report of the Group Auditor
Report on other legal requirements
Balance Sheet
Income Statement
Notes to the Statutory Financial Statements
Proposals of the Board of Directors to the Annual Shareholder's Meeting
Report of the Statutory Auditor
